Sana Biotechnology (SANA) Short term Debt (2021 - 2026)

Sana Biotechnology (SANA) posted Short term Debt of $53.6 million for Q1 2026, up 33.22% sequentially from $40.2 million in Q4 2025.

Sana Biotechnology (SANA) Short term Debt (2021 - 2026) Analysis & Trends

Sana Biotechnology has reported Short term Debt for 5 years, with the latest figure at $53.6 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $53.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (changed N/A YoY) and the FY2025 annual result came in at $40.2 million, changed N/A from the prior year.
Short term Debt advanced to $53.6 million in Q1 2026 per SANA's latest filing, from $40.2 million in the prior quarter.
Over five years, Short term Debt peaked at $59.4 million in Q3 2022 and troughed at $40.2 million in Q4 2025.
A 4-year average of $53.3 million and a median of $54.5 million in 2022 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 36.75% in 2022, down 7.71% in 2022.
Over 4 years, Short term Debt stood at $55.3 million in 2022, then rose by 5.55% to $58.4 million in 2023, then sank by 31.18% to $40.2 million in 2025, then soared by 33.22% to $53.6 million in 2026.
According to Business Quant data, Short term Debt over the past three periods registered $53.6 million, $40.2 million, and $58.4 million for Q1 2026, Q4 2025, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Sana Biotechnology	1.06 Bn	1.06 Bn	-

Download Data